Marble Harbor Investment Counsel LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

Marble Harbor Investment Counsel LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 342,471 shares of the biopharmaceutical company’s stock after selling 9,439 shares during the quarter. Pfizer comprises approximately 1.1% of Marble Harbor Investment Counsel LLC’s holdings, making the stock its 26th largest holding. Marble Harbor Investment Counsel LLC’s holdings in Pfizer were worth $9,582,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Gilbert & Cook Inc. boosted its position in Pfizer by 3.8% during the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 945 shares during the period. Gryphon Financial Partners LLC grew its stake in shares of Pfizer by 43.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 8,194 shares in the last quarter. Fiera Capital Corp purchased a new stake in shares of Pfizer during the 4th quarter valued at about $718,000. Financial Advocates Investment Management lifted its position in Pfizer by 3.2% during the 4th quarter. Financial Advocates Investment Management now owns 43,856 shares of the biopharmaceutical company’s stock worth $1,263,000 after acquiring an additional 1,359 shares in the last quarter. Finally, Balentine LLC boosted its holdings in Pfizer by 23.7% in the 4th quarter. Balentine LLC now owns 92,725 shares of the biopharmaceutical company’s stock worth $2,670,000 after acquiring an additional 17,755 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.4 %

Shares of NYSE:PFE opened at $29.27 on Monday. The company’s fifty day moving average is $29.21 and its two-hundred day moving average is $28.13. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.42. The stock has a market capitalization of $165.86 billion, a price-to-earnings ratio of -487.83, a price-to-earnings-growth ratio of 1.04 and a beta of 0.68.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.74%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PFE shares. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, September 9th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.